Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform
Zomedica Corp. Common Shares (ZOM)
US:NYSE Investor Relations:
investors.zomedica.com
Company Research
Source: GlobeNewswire
ANN ARBOR, Mich., June 13, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it has completed initial development work on a blood-borne lymphoma cancer assay intended for use with its canine cancer liquid biopsy platform. According to the American Veterinary Medical Association, one in four dogs will develop cancer during their lifetime. Lymphomas represent approximately 10-25% of all cancers diagnosed in dogs. The lymphoma assay, designated ZM-022, is designed to identify specific genetic abnormalities using fluorescence in situ hybridization (FISH). FISH tests are regularly used for cancers in human medicine, such as the HER2 breast cancer test. The assay is being developed for use on Zomedica’s liquid biopsy platform, which is expected to be available for sale in 2020. As previously announced, Zomedica is also developing assays for the detection of hemangiosarcoma
Show less
Read more
Impact Snapshot
Event Time:
ZOM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZOM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZOM alerts
High impacting Zomedica Corp. Common Shares news events
Weekly update
A roundup of the hottest topics
ZOM
News
- Zomedica Corp. (AMEX:ZOM) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity [Yahoo! Finance]Yahoo! Finance
- Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in LiquidityAccesswire
- Zomedica to Present at the EF Hutton Annual Global Conference on May 15, 2024 [Yahoo! Finance]Yahoo! Finance
- Zomedica to Present at the EF Hutton Annual Global Conference on May 15, 2024Accesswire
ZOM
Earnings
- 8/10/23 - Miss
ZOM
Sec Filings
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 4/29/24 - Form ARS
- ZOM's page on the SEC website